Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Surveillance on Extended Spectrum β-lactamase and AmpC β-lactamase producing gram negative isolates from nosocomial infections

Surveillance on Extended Spectrum β-lactamase and AmpC β-lactamase producing gram negative... Background: Extended spectrum beta lactamases (ESBLs) and AmpC beta-lactamases conferring resistance to expanded-spectrum cephalosporins, continue to be a major problem in health care settings.Knowlege of their occurrence is essential to guide the clinicians towards the appropriate anti-microbial treatment. The purpose of this study is to evaluate simultaneously the incidence of ESBL and AmpC β-lactamases, and to analyse their antibiotic susceptibility in nosocomial gram-negative clinical isolates from a tertiary care hospital. Material and Methods: A total number of 180 consecutive non repetitive clinical isolates of Escherichia coli (n=67), Klebsiella pneumoniae (n=9) ),P.aeruginosa (n=23 ), Proteus spp. (n=5 ),citrobacter spp. (n=3), Enterobacter spp. ( n=2) and Acinetobacter spp. (n=13) obtained over a period of four months (February to May, 2011) , were screened for ESBL AmpC production by Kirby Bauer disk diffusion method and suspected isolates were subjected to double disk synergy, combined disk, MIC reduction and AmpC disk tests for confirmation. Results: 37(20.55%) and 32(17.77%) were found to be ESBL and AmpC producers from 80(44.44%) and 59 (32.77%) screened out isolates respectively. Organismwise distribution of ESBL and AmpC isolates showed E.coli (23.18% & 15.94%), Klebsiella spp (26.15% & 18.46) , P.aeruginosa (17.39% & 13.04%) and Acinetobacter spp ( 0 & 46.15%) respectively and they were significantly multidrug resistance too. Conclusion: The incidence of ESBLs and AmpC was found to be lower in our hospital. Both the double disk synergy and combined disk tests showed equal efficacy in screening of ESBLs and result emphasizes the necessity of confirmation by MIC reduction test. Given the need for a test for AmpC ß-lactamases, the AmpC disk test could fill a current gap in diagnostic microbiology as it is reliable, simple and rapid. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Clinical Microbiology iMedPub, Internet Medical Publishing

Loading next page...
 
/lp/imedpub-internet-medical-publishing/surveillance-on-extended-spectrum-lactamase-and-ampc-lactamase-7nQrmGT33p

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
iMedPub, Internet Medical Publishing
ISSN
1989-8436
Publisher site
See Article on Publisher Site

Abstract

Background: Extended spectrum beta lactamases (ESBLs) and AmpC beta-lactamases conferring resistance to expanded-spectrum cephalosporins, continue to be a major problem in health care settings.Knowlege of their occurrence is essential to guide the clinicians towards the appropriate anti-microbial treatment. The purpose of this study is to evaluate simultaneously the incidence of ESBL and AmpC β-lactamases, and to analyse their antibiotic susceptibility in nosocomial gram-negative clinical isolates from a tertiary care hospital. Material and Methods: A total number of 180 consecutive non repetitive clinical isolates of Escherichia coli (n=67), Klebsiella pneumoniae (n=9) ),P.aeruginosa (n=23 ), Proteus spp. (n=5 ),citrobacter spp. (n=3), Enterobacter spp. ( n=2) and Acinetobacter spp. (n=13) obtained over a period of four months (February to May, 2011) , were screened for ESBL AmpC production by Kirby Bauer disk diffusion method and suspected isolates were subjected to double disk synergy, combined disk, MIC reduction and AmpC disk tests for confirmation. Results: 37(20.55%) and 32(17.77%) were found to be ESBL and AmpC producers from 80(44.44%) and 59 (32.77%) screened out isolates respectively. Organismwise distribution of ESBL and AmpC isolates showed E.coli (23.18% & 15.94%), Klebsiella spp (26.15% & 18.46) , P.aeruginosa (17.39% & 13.04%) and Acinetobacter spp ( 0 & 46.15%) respectively and they were significantly multidrug resistance too. Conclusion: The incidence of ESBLs and AmpC was found to be lower in our hospital. Both the double disk synergy and combined disk tests showed equal efficacy in screening of ESBLs and result emphasizes the necessity of confirmation by MIC reduction test. Given the need for a test for AmpC ß-lactamases, the AmpC disk test could fill a current gap in diagnostic microbiology as it is reliable, simple and rapid.

Journal

Archives of Clinical MicrobiologyiMedPub, Internet Medical Publishing

Published: May 30, 2012

There are no references for this article.